Submissions from 2023
Expert Agreement on Identification and Characterization of Electrographic Seizures, James Castellano, Rishabh Jain, Wesley Kerr, Laura Szklarski, Arun Antony, Thander Aung, Maria Baldwin, Niravkumar Barot, Joanna Fong-Isariyawongse, and Andrew Zillgitt
Submissions from 2022
9-month course of refractory anti-NMDA receptor encephalitis with initial negative markers: diagnostic and therapeutic challenges, Camilla Cascardo, Alexander Ismail, Francisco Davila, and Nicole Marijanovich
Neurologic complications of cancer, David Green
Status epilepticus, David Green
Stroke Teams: Can an Emergency Room Team provide quicker door-to-needle times than a Neurology Team?, Scott Klein, Amy Wallace, Dawn Zelenka, and Joshua Nass
Responsive Neurostimulation (RNS) of the Centromedian Nucleus of the Thalamus for the Treatment of Drug Resistant Idiopathic Generalized Epilepsy, Angelique Manasseh, Hannah Guider, Brooklynn Bondy, Ayman Haykal, Nour Baki, Ashleigh Terrell, Michael Staudt, Christopher Parres, and Andrew Zillgitt
Submissions from 2021
Evoked potentials in the diagnosis of peripheral and central nervous system disorders. Pediatric Epilepsy: New and Novel Approaches, Daniel L. Menkes
The Guillain Barre Syndrome, Daniel L. Menkes
Update on the Guillain-Barre Syndrome, Daniel L. Menkes
Neurologic prognostication after cardiac arrest, Christopher Parres
Adult Clinical MEG Cases, Andrew Zillgitt
Clinical Utility of Magnetoencephalography (MEG): Standard clinical practice and coherence source imaging, Andrew Zillgitt
Managing critical care seizures and drug resistant epilepsy, Andrew Zillgitt
Temporal Lobe Epilepsy: Surgical treatment options for the most common, but heterogenous, and at times hidden, focal epilepsy, Andrew Zillgitt
The Most Common Focal Epilepsies: Differentiating temporal lobe epilepsy and frontal lobe epilepsy, Andrew Zillgitt
The utility of MEG in the epilepsy presurgical evaluation Pediatric Epilepsy: New and Novel Approaches, Andrew Zillgitt
Submissions from 2018
CSF lamp2 concentrations are decreased in female Parkinson's disease patients with LRRK2 mutations., Andrea C. Klaver, Mary P Coffey, and David A. Loeffler